Literature DB >> 29687473

Sequential prevalence estimation with pooling and continuous test outcomes.

Ngoc T Nguyen1, Ebru K Bish1, Hrayer Aprahamian1.   

Abstract

Prevalence estimation is crucial for controlling the spread of infections and diseases and for planning of health care services. Prevalence estimation is typically conducted via pooled, or group, testing due to limited testing budgets. We study a sequential estimation procedure that uses continuous pool readings and considers the dilution effect of pooling so as to efficiently estimate an unknown prevalence rate. Embedded into the sequential estimation procedure is an optimization model that determines the optimal pooling design (number of pools and pool sizes) under a limited testing budget, considering the trade-off between testing cost and estimation accuracy. Our numerical study indicates that the proposed sequential estimation procedure outperforms single-stage procedures, or procedures that use binary test outcomes. Further, the sequential procedure provides robust prevalence estimates in cases where the initial estimate of the unknown prevalence rate is poor, or the assumed distribution of the biomarker load in infected subjects is inaccurate. Thus, when limited and unreliable information is available about the current status of, or biomarker dynamics related to, an infection, the sequential procedure becomes an attractive estimation strategy, due to its ability to mitigate the initial bias.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  continuous test outcome; dilution effect; limited resources; pool design; pooling; prevalence estimation

Mesh:

Substances:

Year:  2018        PMID: 29687473     DOI: 10.1002/sim.7657

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  Performance of rapid IgM-IgG combined antibody tests in the occupational surveillance of COVID-19 in Colombian enterprises

Authors:  Álvaro J Idrovo; José Moreno-Montoya; Carlos E Pinzón-Flórez
Journal:  Biomedica       Date:  2020-10-30       Impact factor: 0.935

2.  A robust pooled testing approach to expand COVID-19 screening capacity.

Authors:  Douglas R Bish; Ebru K Bish; Hussein El-Hajj; Hrayer Aprahamian
Journal:  PLoS One       Date:  2021-02-08       Impact factor: 3.240

3.  Assessment of Successful qRT-PCR of SARS-CoV-2 Assay in Pool Screening Using Isopropyl Alcohol Purification Step in RNA Extraction.

Authors:  Mayank Gangwar; Alka Shukla; Virendra Kumar Patel; Pradyot Prakash; Gopal Nath
Journal:  Biomed Res Int       Date:  2021-06-08       Impact factor: 3.411

4.  Design of a High-Throughput Real-Time PCR System for Detection of Bovine Respiratory and Enteric Pathogens.

Authors:  Nicole B Goecke; Bodil H Nielsen; Mette B Petersen; Lars E Larsen
Journal:  Front Vet Sci       Date:  2021-06-24

5.  Pooled RNA sample reverse transcriptase real time PCR assay for SARS CoV-2 infection: A reliable, faster and economical method.

Authors:  Ekta Gupta; Abhishek Padhi; Arvind Khodare; Reshu Agarwal; Krithiga Ramachandran; Vibha Mehta; Mousumi Kilikdar; Shantanu Dubey; Guresh Kumar; Shiv Kumar Sarin
Journal:  PLoS One       Date:  2020-07-30       Impact factor: 3.240

6.  A methodology for deriving the sensitivity of pooled testing, based on viral load progression and pooling dilution.

Authors:  Ngoc T Nguyen; Hrayer Aprahamian; Ebru K Bish; Douglas R Bish
Journal:  J Transl Med       Date:  2019-08-06       Impact factor: 5.531

Review 7.  The outlook for diagnostic purposes of the 2019-novel coronavirus disease.

Authors:  Safa Tahmasebi; Elnaz Khosh; Abdolreza Esmaeilzadeh
Journal:  J Cell Physiol       Date:  2020-05-26       Impact factor: 6.513

8.  COVID-19 Diagnosed by Real-Time Reverse Transcriptase-Polymerase Chain Reaction in Nasopharyngeal Specimens of Suspected Cases in a Tertiary Care Center: A Descriptive Cross-sectional Study.

Authors:  Narayani Maharjan; Niresh Thapa; Bibek Pun Magar; Muna Maharjan; Jiancheng Tu
Journal:  JNMA J Nepal Med Assoc       Date:  2021-05-25       Impact factor: 0.406

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.